Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.52
EXEL's Cash to Debt is ranked lower than
85% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. EXEL: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
EXEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.45 Max: N/A
Current: 0.52
Equity to Asset -0.20
EXEL's Equity to Asset is ranked lower than
93% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EXEL: -0.20 )
Ranked among companies with meaningful Equity to Asset only.
EXEL' s Equity to Asset Range Over the Past 10 Years
Min: -0.76  Med: 0.13 Max: 0.8
Current: -0.2
-0.76
0.8
F-Score: 4
Z-Score: -6.49
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -393.30
EXEL's Operating margin (%) is ranked lower than
68% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. EXEL: -393.30 )
Ranked among companies with meaningful Operating margin (%) only.
EXEL' s Operating margin (%) Range Over the Past 10 Years
Min: -893.86  Med: -133.43 Max: 30.91
Current: -393.3
-893.86
30.91
Net-margin (%) -532.13
EXEL's Net-margin (%) is ranked lower than
73% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. EXEL: -532.13 )
Ranked among companies with meaningful Net-margin (%) only.
EXEL' s Net-margin (%) Range Over the Past 10 Years
Min: -1069.42  Med: -106.99 Max: 26.14
Current: -532.13
-1069.42
26.14
ROA (%) -57.28
EXEL's ROA (%) is ranked lower than
74% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. EXEL: -57.28 )
Ranked among companies with meaningful ROA (%) only.
EXEL' s ROA (%) Range Over the Past 10 Years
Min: -64.61  Med: -27.47 Max: 20.08
Current: -57.28
-64.61
20.08
ROC (Joel Greenblatt) (%) -6271.94
EXEL's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. EXEL: -6271.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5996.1  Med: -429.81 Max: 766.96
Current: -6271.94
-5996.1
766.96
Revenue Growth (3Y)(%) -61.20
EXEL's Revenue Growth (3Y)(%) is ranked lower than
87% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. EXEL: -61.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.2  Med: 2.45 Max: 25.6
Current: -61.2
-61.2
25.6
» EXEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

EXEL Guru Trades in Q4 2014

Jim Simons 178,033 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2015

EXEL Guru Trades in Q1 2015

John Burbank 78,200 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

EXEL Guru Trades in Q2 2015

Charles Brandes 25,400 sh (New)
» More
Q3 2015

EXEL Guru Trades in Q3 2015

Charles Brandes 25,400 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 24.68
EXEL's P/S is ranked lower than
74% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. EXEL: 24.68 )
Ranked among companies with meaningful P/S only.
EXEL' s P/S Range Over the Past 10 Years
Min: 1.65  Med: 7.97 Max: 50.5
Current: 24.68
1.65
50.5
Current Ratio 3.71
EXEL's Current Ratio is ranked lower than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. EXEL: 3.71 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.37 Max: 9.35
Current: 3.71
0.84
9.35
Quick Ratio 3.67
EXEL's Quick Ratio is ranked lower than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. EXEL: 3.67 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.37 Max: 9.35
Current: 3.67
0.84
9.35
Days Inventory 278.76
EXEL's Days Inventory is ranked lower than
82% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. EXEL: 278.76 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 470.86  Med: 471.31 Max: 471.76
Current: 278.76
470.86
471.76
Days Sales Outstanding 36.62
EXEL's Days Sales Outstanding is ranked higher than
74% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. EXEL: 36.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 31.33 Max: 82.11
Current: 36.62
4.51
82.11
Days Payable 231.56
EXEL's Days Payable is ranked higher than
86% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. EXEL: 231.56 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 1145.74  Med: 2098.33 Max: 3050.92
Current: 231.56
1145.74
3050.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.97
EXEL's Price/Median PS Value is ranked lower than
91% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. EXEL: 2.97 )
Ranked among companies with meaningful Price/Median PS Value only.
EXEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1.14 Max: 4.83
Current: 2.97
0.25
4.83
Price/Graham Number 1.19
EXEL's Price/Graham Number is ranked higher than
70% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. EXEL: 1.19 )
Ranked among companies with meaningful Price/Graham Number only.
EXEL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.27  Med: 1.53 Max: 4.11
Current: 1.19
0.27
4.11
Earnings Yield (Greenblatt) (%) -11.90
EXEL's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. EXEL: -11.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11.9  Med: 12.30 Max: 17.1
Current: -11.9
-11.9
17.1

More Statistics

Revenue(Mil) $35
EPS $ -0.92
Beta1.58
Short Percentage of Float30.34%
52-Week Range $1.86 - 6.81
Shares Outstanding(Mil)227.22

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 47 110
EPS($) -0.81 -0.81
EPS without NRI($) -0.81 -0.81

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EX9.Germany,
Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.
» More Articles for NAS:EXEL

Headlines

Articles On GuruFocus.com
The Best-Performing Non-S&P Stocks of 2015 Dec 30 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 

More From Other Websites
Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10 Feb 04 2016
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study Feb 02 2016
Exelixis Rises on Positive Late-Stage Trial Results Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis's Cabozantinib Granted Priority Review in the U.S. Jan 29 2016
Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for... Jan 28 2016
Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority... Jan 28 2016
Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
[video]'Mad Money' Lightning Round: Move on From Broadcom Jan 20 2016
Exelixis upgraded by Leerink Partners Jan 19 2016
Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a... Jan 11 2016
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and... Jan 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK